Immune reconstitution inflammatory syndrome in AIDS patient after successful induction of virological suppression with cabotegravir/rilpivirine
  • Rami Al-Handola
    Department of Internal Medicine, Hurley Medical Center, Michigan State University/College of Human Medicine, Flint, MI, USA https://orcid.org/0009-0001-0689-9382
  • Justine Chinnappan
    Department of Internal Medicine, Hurley Medical Center, Michigan State University/College of Human Medicine, Flint, MI, USA
  • Mohammad Bakeer
    Department of Internal Medicine, Hurley Medical Center, Michigan State University/College of Human Medicine, Flint, MI, USA
  • Danielle Osterholzer
    Department of Internal Medicine, Hurley Medical Center, Michigan State University/College of Human Medicine, Flint, MI, USA; Division of Infectious Diseases, Department of Internal Medicine, Hurley Medical Center, Michigan State University/College of Human Medicine, Flint, MI, USA

Keywords

Cabotegravir/Rilpivirine, Immune Reconstitution Inflammatory Syndrome, IRIS, AIDS, HIV

Abstract

Long-acting (LA) cabotegravir/rilpivirine (CAB/RPV) is a complete regimen for the management of human immunodeficiency virus type 1 (HIV-1) infection to replace their oral antiretroviral therapy (ART) when they have been virologically suppressed. We present a case of successful achievement of undetectable HIV RNA viral load levels in an acquired immunodeficiency syndrome (AIDS) patient with long-standing virologic failure within two months of CAB/RPV LA initiation. This was later complicated by immune reconstitution inflammatory syndrome (IRIS) due to Mycobacterium avium-intracellulare (MAI) infection and hepatitis B virus (HBV) reactivation.

VIEW THE ENTIRE ARTICLE

References

  • Swindells S, Andrade-Villanueva J-F, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020;382:1112–1123.
  • Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Hernández-Mora MG, et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr 2020;85:498–506.
  • Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV 2021;8:e679–e689.
  • McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States. Adv Ther 2021;38:4961–4974.
  • Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med 2016;13:e1002183.
  • Christopoulos KA, Grochowski J, Mayorga-Muno F, Hickey, MD, Imbert E, Szumowski JD, et al. First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic. Clin Infect Dis 2023;76:e645–e651.
  • Tappuni AR. Immune reconstitution inflammatory syndrome. Adv Dent Res 2011;23: 90–96.
  • Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013;310:1664.
  • Seto W-K, Chan TS-Y, Hwang Y-Y, Wong DK-H, Fung J, Liu KS-H, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology 2017;65:1451–1461.

    • Views: 394
    HTML downloads: 45
    PDF downloads: 351

    Published: 2023-07-13
    Issue: 2023: Vol 10 No 8 (view)

    How to cite:
    1.
    Al-Handola R, Chinnappan J, Bakeer M, Osterholzer D. Immune reconstitution inflammatory syndrome in AIDS patient after successful induction of virological suppression with cabotegravir/rilpivirine. EJCRIM 2023;10 doi:10.12890/2023_003981.

    Most read articles by the same author(s)